Allelic loss of chromosome 4q21≈23 associates with hepatitis B virus-related hepatocarcinogenesis and elevated alpha-fetoprotein

Hepatology

Volumn 40, Issue 4, 2004, Pages 847-854

  Yeh, Shiou Hwei ^a,b   Lin, Ming Wei ^c,d   Lu, Shu Fen ^b   Wu, Dai Chen ^a   Tsai, Shih Feng ^a   Tsai, Ching Yi ^b   Lai, Ming Yang ^e,f   Hsu, Hey Chi ^e   Chen, Ding Shinn ^b,e,f   Chen, Pei Jer ^b,e,f  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; AGED; ALLELIC EXCLUSION; ALLELIC IMBALANCE; ALLELIC LOSS; ARTICLE; CHROMOSOME 4Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION 4; CHROMOSOME LOSS; CHROMOSOME MAP; CONTROLLED STUDY; DELETION MUTANT; DOWN REGULATION; FEMALE; GENE MUTATION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; VIRUS INFECTION;

EID: 84984563004     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20409     Document Type: Article

References (49)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-156.
2. Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 1997;12:S294-S308.
3. Chen PJ, Chen DS. Hepatitis B virus infection and hepatocellular carcinoma: molecular genetics and clinical perspectives. Semin Liver Dis 1999;19:253-262.
4. Buendia MA. Genetics of hepatocellular carcinoma. Semin Cancer Biol 2000;10:185-200.
5. Kusano N, Shiraishi K, Kubo K, Oga A, Okita K, Sasaki K. Genetic aberrations detected by comparative genomic hybridization in hepatocellular carcinomas: their relationship to clinicopathological features. HEPATOLOGY 1999;29:1858-1862.
6. Okabe H, Ikai I, Matsuo K, Satoh S, Momoi H, Kamikawa T, et al. Comprehensive allelotype study of hepatocellular carcinoma: potential differences in pathways to hepatocellular carcinoma between hepatitis B virus-positive and -negative tumors. HEPATOLOGY 2000;31:1073-1079.
7. Marchio A, Pineau P, Meddeb M, Terris B, Tiollais P, Bernheim A, et al. Distinct chromosomal abnormality pattern in primary liver cancer of non-B, non-C patients. Oncogene 2000;19:3733-3738.
8. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001;120:1763-1773.
9. Boige V, Laurent-Puig P, Fouchet P, Flejou JF, Monges G, Bedossa P, et al. Concerted nonsyntenic allelic losses in hyperploid hepatocellular carcinoma as determined by a high-resolution allelotype. Cancer Res 1997;57:1986-1990.
10. Marchio A, Meddeb M, Pineau P, Danglot G, Tiollais P, Bernheim A, et al. Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 1997;18:59-65.
11. Nagai H, Pineau P, Tiollais P, Buendia MA, Dejean A. Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene 1997;14:2927-2933.
12. McGlynn KA, Edmonson MN, Michielli RA, London WT, Lin WY, Chen GC, et al. A phylogenetic analysis identifies heterogeneity among hepatocellular carcinomas. HEPATOLOGY 2002;36:1341-1348.
13. Polascik TJ, Cairns P, Chang WY, Schoenberg MP, Sidransky D. Distinct regions of allelic loss on chromosome 4 in human primary bladder carcinoma. Cancer Res 1995;55:5396-5399.
14. Hampton GM, Larson AA, Baergen RN, Sommers RL, Kern S, Cavenee WK. Simultaneous assessment of loss of heterozygosity at multiple microsatellite loci using semi-automated fluorescence-based detection: subregional mapping of chromosome 4 in cervical carcinoma. Proc Natl Acad Sci U S A 1996;93:6704-6709.
15. Hammoud ZT, Kaleem Z, Cooper JD, Sundaresan RS, Patterson GA, Goodfellow PJ. Allelotype analysis of esophageal adenocarcinomas: evidence for the involvement of sequences on the long arm of chromosome 4. Cancer Res 1996;56:4499-4502.
16. Pershouse MA, El-Naggar AK, Hurr K, Lin H, Yung WK, Steck PA. Deletion mapping of chromosome 4 in head and neck squamous cell carcinoma. Oncogene 1997;14:369-373.
17. McGowan-Jordan IJ, Speevak MD, Blakey D, Chevrette M. Suppression of tumorigenicity in human teratocarcinoma cell line PA-1 by introduction of chromosome 4. Cancer Res 1994;54:2568-2572.
18. Pershouse MA, Ligon AH, Pereira-Smith OM, Killary AM, Yung WK, Steck PA. Suppression of transformed phenotype and tumorigenicity after transfer of chromosome 4 into U251 human glioma cells. Genes Chromosomes Cancer 1997;20:260-267.
19. Piao Z, Park C, Park JH, Kim H. Deletion mapping of chromosome 4q in hepatocellular carcinoma. Int J Cancer 1998;79:356-360.
20. Hammond C, Jeffers L, Carr BI, Simon D. Multiple genetic alterations, 4q28, a new suppressor region, and potential gender differences in human hepatocellular carcinoma. HEPATOLOGY 1999;29:1479-1485.
21. Bando K, Nagai H, Matsumoto S, Koyama M, Kawamura N, Onda M, et al. Identification of a 1-cM region of common deletion on 4q35 associated with progression of hepatocellular carcinoma. Genes Chromosomes Cancer 1999;25:284-289.
22. Rumpel CA, Powell SM, Moskaluk CA. Mapping of genetic deletions on the long arm of chromosome 4 in human esophageal adenocarcinomas. Am J Pathol 1999;154:1329-1334.
23. Bluteau O, Beaudoin JC, Pasturaud P, Belghiti J, Franco D, Bioulac-Sage P, et al. Specific association between alcohol intake, high grade of differentiation and 4q34-q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping. Oncogene 2002;21:1225-1232.
24. Yeh SH, Chen PJ, Lai MY, Chen DS. Allelic loss on chromosomes 4q and 16q in hepatocellular carcinoma: association with elevated alpha-fetoprotein production. Gastroenterology 1996;110:184-192.
25. Yeh CN, Lee WC, Chen MF, Tsay PK. Predictors of long-term disease-free survival after resection of hepatocellular carcinoma: two decades of experience at Chang Gung Memorial Hospital. Ann Surg Oncol 2003;10:916-921.
26. Yeh SH, Chen PJ, Chen HL, Lai MY, Wang CC, Chen DS. Frequent genetic alterations at the distal region of chromosome 1p in human hepatocellular carcinomas. Cancer Res 1994;54:4188-4192.
27. Wang HW, Wu HL, Chen DS, Chen PJ. Identification of the functional regions required for hepatitis D virus replication and transcription by linker-scanning mutagenesis of viral genome. Virology 1997;239:119-131.
28. Tanaka K, Ikematsu H, Hirohata T, Kashiwagi S. Hepatitis C virus infection and risk of hepatocellular carcinoma among Japanese: possible role of type 1b (II) infection. J Natl Cancer Inst 1996;88:742-746.
29. Pennisi E. Human genome. Reaching their goal early, sequencing labs celebrate. Science 2003;300:409.
30. Yeh SH, Chen PJ, Shau WY, Chen YW, Lee PH, Chen JT, et al. Chromosomal allelic imbalance evolving from liver cirrhosis to hepatocellular carcinoma. Gastroenterology 2001;121:699-709.
31. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-353.
32. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-1947.
33. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-440.
34. Mollenhauer J, Wiemann S, Scheurlen W, Korn B, Hayashi Y, Wilgenbus KK, et al. DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. Nat Genet 1997;17:32-39.
35. Bluteau O, Legoix P, Bayer J, Bioulac-Sage P, Flejou JF, Capron F, et al. Semi-automated quantitative method for detecting the loss of heterozygosity at the long arm of chromosome 4 in hepatocellular carcinoma. Gastroenterol Clin Biol 1999;23:1225-1232 [in French].
36. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003;9:416-423.
37. Tornillo L, Carafa V, Richter J, Sauter G, Moch H, Minola E, et al. Marked genetic similarities between hepatitis B virus-positive and hepatitis C virus-positive hepatocellular carcinomas. J Pathol 2000;192:307-312.
38. Sakakura C, Hagiwara A, Taniguchi H, Yamaguchi T, Yamagishi H, Takahashi T, et al. Chromosomal aberrations in human hepatocellular carcinomas associated with hepatitis C virus infection detected by comparative genomic hybridization. Br J Cancer 1999;80:2034-2039.
39. Delpuech O, Trabut JB, Carnot F, Feuillard J, Brechot C, Kremsdorf D. Identification, using cDNA macroarray analysis, of distinct gene expression profiles associated with pathological and virological features of hepatocellular carcinoma. Oncogene 2002;21:2926-2937.
40. Honda M, Kaneko S, Kawai H, Shirota Y, Kobayashi K. Differential gene expression between chronic hepatitis B and C hepatic lesion. Gastroenterology 2001;120:955-966.
41. Iizuka N, Oka M, Yamada-Okabe H, Mori N, Tamesa T, Okada T, et al. Differential gene expression in distinct virologie types of hepatocellular carcinoma: association with liver cirrhosis. Oncogene 2003;22:3007-3014.
42. Iizuka N, Oka M, Yamada-Okabe H, Mori N, Tamesa T, Okada T, et al. Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res 2002;62:3939-3944.
43. Otsuka M, Aizaki H, Kato N, Suzuki T, Miyamura T, Omata M, et al. Differential cellular gene expression induced by hepatitis B and C viruses. Biochem Biophys Res Commun 2003;300:443-447.
44. Kawai HF, Kaneko S, Honda M, Shirota Y, Kobayashi K. alpha-fetoprotein- producing hepatoma cell lines share common expression profiles of genes in various categories demonstrated by cDNA microarray analysis. HEPATOLOGY 2001;33:676-691.
45. Terada Y, Imoto I, Nagai H, Suwa K, Momoi M, Tajiri T, et al. An 8-cM interstitial deletion on 4q21-q22 in DNA from an infant with hepatoblastoma overlaps with a commonly deleted region in adult liver cancers. Am J Med Genet 2001;103:176-180.
46. Ogden SK, Lee KC, Wernke-Dollries K, Stratton SA, Aronow B, Barton MC. p53 targets chromatin structure alteration to repress alpha-fetoprotein gene expression. J Biol Chem 2001;276:42057-42062.
47. Huang MC, Li KK, Spear BT. The mouse alpha-fetoprotein promoter is repressed in HepG2 hepatoma cells by hepatocyte nuclear factor-3 (FOXA). DNA Cell Biol 2002;21:561-569.
48. Kataoka H, Bonnefin P, Vieyra D, Feng X, Hara Y, Miura Y, et al. ING1 represses transcription by direct DNA binding and through effects on p53. Cancer Res 2003;63:5785-5792.
49. Vacher J, Tilghman SM. Dominant negative regulation of the mouse alpha-fetoprotein gene in adult liver. Science 1990;250:1732-1735.